Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01182350 · OUTCOME

9-month Overall Survival (OS) Rate

Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG) · Source last updated 2019-09-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
90% Confidence Interval
Time frame
9 months

What was measured

9-month overall survival is the percentage of participants remaining alive 9 months from registration.

Analysis population: The analysis population is comprised of the subset of participants who underwent biopsy, obtained a molecularly-based treatment assignment and started assigned chemoradiation therapy.

Groups in this outcome

All Patients Starting Assigned Chemoradiation

Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days). Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
All Patients Starting Assigned Chemoradiation45

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 90% Confidence Interval
GroupValueSpreadLowerUpperComment
All Patients Starting Assigned Chemoradiation64.4Not reported51.176.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        51.1
        upper Limit
        76.3
        value
        64.4
denoms
  1. counts
    1. group Id
      OG000
      value
      45
    units
    Participants
description
9-month overall survival is the percentage of participants remaining alive 9 months from registration.
dispersion Type
90% Confidence Interval
groups
  1. description
    Protocol treatment lasts approximately 52 weeks including a 4-week interim period once radiation therapy is completed and a maintenance phase (cycle duration=28 days). Treatment directed based on tumor biopsy results requires classification of patients into 1 of 4 potential cohorts: O\^6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (negative versus positive) and epidermal growth factor receptor (EGFR) overexpression status (negative versus positive).
    id
    OG000
    title
    All Patients Starting Assigned Chemoradiation
param Type
NUMBER
population Description
The analysis population is comprised of the subset of participants who underwent biopsy, obtained a molecularly-based treatment assignment and started assigned chemoradiation therapy.
reporting Status
POSTED
time Frame
9 months
title
9-month Overall Survival (OS) Rate
type
PRIMARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice